Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1989 Oct 14;299(6705):942–945. doi: 10.1136/bmj.299.6705.942

Acute and chronic arterial and venous effects of captopril in congestive cardiac failure.

S Capewell 1, D Taverner 1, W J Hannan 1, A L Muir 1
PMCID: PMC1837786  PMID: 2508945

Abstract

OBJECTIVE--To determine whether captopril alters peripheral venous tone in patients with congestive cardiac failure. DESIGN--Open study of patients at start of captopril treatment and three months later. SETTING--A hospital gamma camera laboratory. PATIENTS--16 Men with congestive cardiac failure in New York Heart Association class II or III, aged 57-73. INTERVENTIONS--Patients were initially given 500 micrograms sublingual glyceryl trinitrate followed by 25 mg oral captopril. The study was then repeated after three months' captopril treatment. MAIN OUTCOME MEASURES--Previously validated non-invasive radionuclide techniques were used to measure changes in central haemodynamic variables and peripheral venous volumes in the calf. RESULTS--After 25 mg captopril there were falls in blood pressure and relative systemic vascular resistance and increases in cardiac index and left ventricular ejection fraction. This was accompanied by a 16% increase in peripheral venous volume (95% confidence interval 13.4% to 18.4%, p less than 0.01), which compared with an 11% increase after 500 micrograms glyceryl trinitrate (10% to 12%, p less than 0.01). Eleven patients were restudied after three months' continuous treatment with captopril. The resting venous volume was higher than it had been initially, by about 10%, and increased by a further 8.4% after 25 mg captopril (5.4% to 11.4%, p less than 0.05). CONCLUSIONS--Captopril is an important venodilator. Venous and arterial dilatation are produced short term and during long term treatment.

Full text

PDF
942

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awan N. A., Evenson M. K., Needham K. E., Win A., Mason D. T. Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. Am Heart J. 1981 Jan;101(1):22–31. doi: 10.1016/0002-8703(81)90379-3. [DOI] [PubMed] [Google Scholar]
  2. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohn J. N., Archibald D. G., Ziesche S., Franciosa J. A., Harston W. E., Tristani F. E., Dunkman W. B., Jacobs W., Francis G. S., Flohr K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  4. Cowley A. J., Rowley J. M., Stainer K. L., Hampton J. R. Captopril therapy for heart failure. A placebo controlled study. Lancet. 1982 Oct 2;2(8301):730–732. doi: 10.1016/s0140-6736(82)90920-5. [DOI] [PubMed] [Google Scholar]
  5. Faxon D. P., Halperin J. L., Creager M. A., Gavras H., Schick E. C., Ryan T. J. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May;101(5):548–556. doi: 10.1016/0002-8703(81)90220-9. [DOI] [PubMed] [Google Scholar]
  6. Fouad F. M., Tarazi R. C., Bravo E. L., Hart N. J., Castle L. W., Salcedo E. E. Long-term control of congestive heart failure with captopril. Am J Cardiol. 1982 Apr 21;49(6):1489–1496. doi: 10.1016/0002-9149(82)90366-6. [DOI] [PubMed] [Google Scholar]
  7. Franciosa J. A., Pierpont G., Cohn J. N. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med. 1977 Apr;86(4):388–393. doi: 10.7326/0003-4819-86-4-388. [DOI] [PubMed] [Google Scholar]
  8. Furberg C. D., Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol. 1985 Apr 1;55(8):1110–1113. doi: 10.1016/0002-9149(85)90756-8. [DOI] [PubMed] [Google Scholar]
  9. Lipkin D. P., Poole-Wilson P. A. Treatment of chronic heart failure: a review of recent drug trials. Br Med J (Clin Res Ed) 1985 Oct 12;291(6501):993–996. doi: 10.1136/bmj.291.6501.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miller R. R., Fennell W. H., Young J. B., Palomo A. R., Quinones M. A. Differential systemic arterial and venous actions and consequent cardiac effects of vasodilator drugs. Prog Cardiovasc Dis. 1982 Mar-Apr;24(5):353–374. doi: 10.1016/0033-0620(82)90019-6. [DOI] [PubMed] [Google Scholar]
  11. Packer M. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. Int J Cardiol. 1985 Feb;7(2):111–120. doi: 10.1016/0167-5273(85)90349-3. [DOI] [PubMed] [Google Scholar]
  12. Packer M., Lee W. H., Yushak M., Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986 Oct 2;315(14):847–853. doi: 10.1056/NEJM198610023151402. [DOI] [PubMed] [Google Scholar]
  13. Rutlen D. L., Wackers F. J., Zaret B. L. Radionuclide assessment of peripheral intravascular capacity: a technique to measure intravascular volume changes in the capacitance circulation in man. Circulation. 1981 Jul;64(1):146–152. doi: 10.1161/01.cir.64.1.146. [DOI] [PubMed] [Google Scholar]
  14. Wathen C. G., Hannan W. J., Adie C. J., Muir A. L. A radionuclide method for the simultaneous study of the effects of drugs on central and peripheral haemodynamics. Br J Clin Pharmacol. 1983 Jul;16(1):45–50. doi: 10.1111/j.1365-2125.1983.tb02142.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES